Hydroxyurea (Synonyms: Hydroxycarbamide)

Name: Hydroxyurea
Brand: MedChemExpress
SKU: HY-B0313
Rating: 5.0 (31 reviews)

Cat. No.: HY-B0313 Pureza: 99.34%: Ficha de datos
COA

SDS
Instrucciones de manejo
FAQs
Technical Support

Hydroxyurea is a cell apoptosis inducer that inhibit DNA synthesis through inhibition of ribonucleotide reductase. Hydroxyurea shows anti-orthopoxvirus activity.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 127-07-1

Tamaño	Stock	Cantidad
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	En stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	En stock	Estimated Time of Arrival: December 31
Solid
500 mg	En stock	Estimated Time of Arrival: December 31
1 g	En stock	Estimated Time of Arrival: December 31
5 g	En stock	Estimated Time of Arrival: December 31
10 g	Obtener un presupuesto
50 g	Obtener un presupuesto

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 31 publication(s) in Google Scholar

Other Forms of Hydroxyurea:

Hydroxyurea (Standard) In-stock
Hydroxyurea-¹⁵N Obtener un presupuesto

31 Publications Citing Use of MCE Hydroxyurea

Cell Imaging/Staining

RT-PCR

Cell Proliferation/Viability Assay

: Hydroxyurea purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 Apr 29;23(1):86. [Abstract]; The cell viability of the indicated T24 cells was determined after 48 h of continuous exposure to multiple concentrations of hydroxyurea (HU).

: Hydroxyurea purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2023 Apr;30(4):922-937. [Abstract]; The interaction between MARVELD1 and PARP1 is greatly enhanced following exposure to Hydroxyurea (HU) in HeLa (8 mM HU; 24 h) and HEK293T cells (4 mM HU; 24 h).

: Hydroxyurea purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2022 Oct 17;7(1):354. [Abstract]; H1650 cells were treated with HA-9104 (5, 10 μM) or Hydroxyurea (HU, 5 mM) for 2 h. Chromatin proteins were isolated from whole cell lysate, followed by Western blotting.

: Hydroxyurea purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Aug 16;13(1):4822. [Abstract]; SA-β-Gal assays for WT and Irf8^-/- BMDMs treated with hydroxyurea (HU, 10 mM) or mitomycin C (MMC, 1µM) for 5 days. Scale bars, 200 μm.

: Hydroxyurea purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Aug 16;13(1):4822. [Abstract]; qPCR analysis of the SASP genes in WT and Irf8^-/- BMDMs treated with hydroxyurea (HU, 10 mM) or mitomycin C (MMC, 1 µM) for 6 days.

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas DNA/RNA Synthesis:

Ver todas las isoformas

RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

Ver todos los productos específicos de isoformas HIV:

Ver todas las isoformas

HIV HIV-1 HIV-2

Actividad biológica
Protocolo
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

Hydroxyurea is a cell apoptosis inducer that inhibit DNA synthesis through inhibition of ribonucleotide reductase. Hydroxyurea shows anti-orthopoxvirus activity.

IC₅₀ & Target

HIV-1

Cellular Effect

Cell Line	Type	Value	Description	References
Erythrocyte	CC₅₀	147 μM Compound: HU	Cytotoxicity against human erythrocytes assessed as cell viability after 3 days alamar blue assay Cytotoxicity against human erythrocytes assessed as cell viability after 3 days alamar blue assay	[PMID: 33109398]
HCT-116	IC₅₀	223 μM Compound: Hydroxyurea	Cytostatic activity against human HCT116 cells Cytostatic activity against human HCT116 cells	[PMID: 19581098]
HeLa S3	ED₅₀	1.96 μg/mL Compound: hydroxyurea	Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
K562	IC₅₀	687.94 μM Compound: Hydroxyurea	Cytotoxicity against Homo sapiens (human) K562 cells after 24 hr by MTT assay Cytotoxicity against Homo sapiens (human) K562 cells after 24 hr by MTT assay	10.1007/s00044-010-9544-6
KB	ED₅₀	5.29 μg/mL Compound: hydroxyurea	Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
L1210	ED₅₀	2.67 μg/mL Compound: hydroxyurea	Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
L1210	IC₅₀	82 μM Compound: Hydroxyurea	Activity against lymphocytic murine leukemia cell line L1210 using MTS/PES microculture tetrazolium assay Activity against lymphocytic murine leukemia cell line L1210 using MTS/PES microculture tetrazolium assay	[PMID: 11784145]
L1210	IC₅₀	85 μM Compound: Hydroxyurea	Antiproliferative activity of compound expressed as concentration that inhibits 50% of growth of L1210 leukemic cell suspension from 24 to 48 hr after compound addition. Antiproliferative activity of compound expressed as concentration that inhibits 50% of growth of L1210 leukemic cell suspension from 24 to 48 hr after compound addition.	[PMID: 2709372]
MCF7	IC₅₀	> 100 μM Compound: Hydroxyurea	Cytostatic activity against human MCF7 cells Cytostatic activity against human MCF7 cells	[PMID: 19581098]
MOLT-3	ED₅₀	3.18 μg/mL Compound: hydroxyurea	Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
MOLT-4	IC₅₀	> 100 μM Compound: Hydroxyurea	Cytostatic activity against human MOLT4 cells Cytostatic activity against human MOLT4 cells	[PMID: 19581098]
NCI-H460	IC₅₀	> 100 μM Compound: Hydroxyurea	Cytostatic activity against human H460 cells Cytostatic activity against human H460 cells	[PMID: 19581098]
P388	IC₅₀	32 μM Compound: Hydroxyurea	Antiproliferative activity of compound expressed as concentration that inhibits 50% of growth of P388 leukemic cell suspension from 24 to 48 hr after compound addition Antiproliferative activity of compound expressed as concentration that inhibits 50% of growth of P388 leukemic cell suspension from 24 to 48 hr after compound addition	[PMID: 2709372]
SW-620	IC₅₀	> 100 μM Compound: Hydroxyurea	Cytostatic activity against human SW620 cells Cytostatic activity against human SW620 cells	[PMID: 19581098]
SW480	ED₅₀	4.79 μg/mL Compound: hydroxyurea	Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
U-937	IC₅₀	115 μM Compound: Hydroxyurea	Cytotoxicity against Homo sapiens (human) U937 cells after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) U937 cells after 96 hr by MTT assay	10.1007/s00044-011-9778-y
U373-MAGI	CC₅₀	252 μM Compound: Hydroxyurea	Increase of 5-Aza-C-mediated cytotoxicity against human U373-MAGI cells at 500 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs measured after 72 hrs by Celltiter-Glo luminescent cell viability assay (Rvb = 387 uM) Increase of 5-Aza-C-mediated cytotoxicity against human U373-MAGI cells at 500 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs measured after 72 hrs by Celltiter-Glo luminescent cell viability assay (Rvb = 387 uM)	[PMID: 27117260]
U373-MAGI	EC₅₀	25.8 μM Compound: Hydroxyurea	Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 500 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection measured at 72 hrs post infection by flow cytometric analysis (Rvb = 136 uM) Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 500 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection measured at 72 hrs post infection by flow cytometric analysis (Rvb = 136 uM)	[PMID: 27117260]
Vero	IC₅₀	0.1 mM Compound: Hydroxyurea (HU)	Compound tested on intracellular parasites Toxoplasma gondii in vero cells after 24 h Compound tested on intracellular parasites Toxoplasma gondii in vero cells after 24 h	[PMID: 15863319]
Vero	IC₅₀	0.1 mM Compound: Hydroxyurea (HU)	Compound tested on vero cells infected with Toxoplasma gondii after 24 h Compound tested on vero cells infected with Toxoplasma gondii after 24 h	[PMID: 15863319]
Vero	IC₅₀	0.5 mM Compound: hydroxyurea	Inhibition of Toxoplasma gondii infected in african green monkey Vero cells Inhibition of Toxoplasma gondii infected in african green monkey Vero cells	[PMID: 17905587]
Vero	IC₅₀	1 mM Compound: hydroxyurea	Inhibition of uninfected african green monkey Vero cells Inhibition of uninfected african green monkey Vero cells	[PMID: 17905587]

In Vitro

Hydroxyurea is used in a number of myeloproliferative, neoplastic, HIV, and non-hematological diseases^[1]. Treatment of cells in primary culture with 30 μM hydroxyurea for 96 hours significantly increases the fractional HbF content. The ^Gγ: ^Aγ-globin mRNA is induced 0.30- to 8-fold in vitro^[2]. Hydroxyurea has been shown to block HIV-1 reverse transcription and/or replication in quiescent peripheral blood mononuclear cells and macrophages^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Hydroxyurea therapy producs consistent reductions in WBC and ANC without improvement in anemia over 17 weeks. Hydroxyurea at 50mg/kg produces a reduced white blood cell count, absolute neutrophil count and no improvement in anemia compared to vehicle treated sickle cell mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ensayo clínico

Peso molecular

76.05

Fòrmula

CH₄N₂O₂

No. CAS

127-07-1

Appearance

Solid

Color

White to off-white

SMILES

O=C(N)NO

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvente y solubilidad

In Vitro:

H₂O : 50 mg/mL (657.46 mM; Need ultrasonic)

DMSO : 50 mg/mL (657.46 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	13.1492 mL	65.7462 mL	131.4924 mL
5 mM	2.6298 mL	13.1492 mL	26.2985 mL
10 mM	1.3149 mL	6.5746 mL	13.1492 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculadora de molaridad
Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (32.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (32.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (32.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 100 mg/mL (1314.92 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Pureza y Documentación

Purity: 99.34%

Select Batch:

Ficha de datos (273 KB) SDS (478 KB)

COA (244 KB) HNMR (125 KB) RP-HPLC (260 KB)

Instrucciones de manejo (2659 KB)

Referencias

[1]. Kovacic P, et al. Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses. 2011 Jan;76(1):24-31. [Content Brief]

[2]. Watanapokasin Y, et al. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Exp Hematol. 2005 Dec;33(12):1486-92. [Content Brief]

[3]. Lori F, et al. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis. 2000 Jun;30 Suppl 2:S193-7. [Content Brief]

[4]. Lebensburger JD, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010 Sep;95(9):1599-603. [Content Brief]

[5]. M B Slabaugh, et al. Hydroxyurea-resistant vaccinia virus: overproduction of ribonucleotide reductase. J Virol. 1986 Nov;60(2):506-14. [Content Brief]

Administraciòn de animales
^[4]

Mice: To determine whether hydroxyurea would improve anemia and/or prevent or diminish the development of organ damage in the absence of HbF induction, hydroxyurea, at doses of 25 mg/kg, 50 mg/kg, and 100 mg/kg, or vehicle is administered five days per week to SCD mice^[4].

MCE no ha confirmado la precisión de estos métodos independientemente. Son solo para referencia.

Referencias

[1]. Kovacic P, et al. Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses. 2011 Jan;76(1):24-31. [Content Brief]

[2]. Watanapokasin Y, et al. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Exp Hematol. 2005 Dec;33(12):1486-92. [Content Brief]

[3]. Lori F, et al. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis. 2000 Jun;30 Suppl 2:S193-7. [Content Brief]

[4]. Lebensburger JD, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010 Sep;95(9):1599-603. [Content Brief]

[5]. M B Slabaugh, et al. Hydroxyurea-resistant vaccinia virus: overproduction of ribonucleotide reductase. J Virol. 1986 Nov;60(2):506-14. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	13.1492 mL	65.7462 mL	131.4924 mL	328.7311 mL
	5 mM	2.6298 mL	13.1492 mL	26.2985 mL	65.7462 mL
	10 mM	1.3149 mL	6.5746 mL	13.1492 mL	32.8731 mL
	15 mM	0.8766 mL	4.3831 mL	8.7662 mL	21.9154 mL
	20 mM	0.6575 mL	3.2873 mL	6.5746 mL	16.4366 mL
	25 mM	0.5260 mL	2.6298 mL	5.2597 mL	13.1492 mL
	30 mM	0.4383 mL	2.1915 mL	4.3831 mL	10.9577 mL
	40 mM	0.3287 mL	1.6437 mL	3.2873 mL	8.2183 mL
	50 mM	0.2630 mL	1.3149 mL	2.6298 mL	6.5746 mL
	60 mM	0.2192 mL	1.0958 mL	2.1915 mL	5.4789 mL
	80 mM	0.1644 mL	0.8218 mL	1.6437 mL	4.1091 mL
	100 mM	0.1315 mL	0.6575 mL	1.3149 mL	3.2873 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Hydroxyurea Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Hydroxyurea127-07-1HydroxycarbamideDNA/RNA SynthesisAutophagyApoptosisHIVOrthopoxvirusHuman immunodeficiency virusInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Nombre del producto			Requested Quantity *
Nombre del solicitante *			Saludo
Direcciòn del E-mail *			Número de teléfono *
Department			Nombre de la Organizaciòn *
City			Provincia
Country or Region *
Observaciones

Nombre del producto			Lot #
Nombre del solicitante *			Direcciòn del E-mail *
Número de teléfono			Department *
Nombre de la Organizaciòn *			Country or Region *
Observaciones

Name
E-mail *

	Sorry, but the email address you supplied was invalid.

Hydroxyurea (Synonyms: Hydroxycarbamide)

Revisión del cliente

Other Forms of Hydroxyurea:

Hydroxyurea Related Antibodies

31 Publications Citing Use of MCE Hydroxyurea

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas DNA/RNA Synthesis:

Ver todos los productos específicos de isoformas HIV:

Actividad biológica

Protocolo

Pureza y Documentación

Referencias

Revisión del cliente

Hydroxyurea Related Antibodies

Calculadora de molaridad

Calculadora de dilución

Complete Stock Solution Preparation Table

Hydroxyurea Related Classifications

Keywords:

Productos vistos recientemente:

Revisión del cliente

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report